KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Survodutide for treatment of obesity: Baseline characteristics of participants in a randomized, double-blind, placebo-controlled, phase 3 trial (SYNCHRONIZE™-1).

Carel W le Roux, Sean Wharton, Biykem Bozkurt, Elke Platz, Gabriele Bleckert, Samina Ajaz Hussain, Martina Brueckmann, Elena Startseva, Isabel M Kloer, Lee M Kaplan

Diabetes Obes Metab 28(1) 337-346

PMID41187967
PMCIDPMC12673442
DOI10.1111/dom.70196
发表日期2025-11-04
入排依据:未发现恶性肿瘤人群证据。
已检查 2 张 PubMed Figure,均未识别为 KM 图:FIGURE 1:AI 判定为 flow diagram;FIGURE 2:AI 判定为 other。
摘要

摘要

AIMS: Survodutide, a novel glucagon receptor and glucagon-like peptide-1 (GLP-1) receptor dual agonist, elicited significant weight loss in a phase 2 trial in individuals with obesity without type 2 diabetes (T2D). Two multinational phase 3 trials are investigating survodutide for obesity management in individuals with or without T2D. We report the baseline characteristics of participants in the SYNCHRONIZE-1 trial in adults with obesity without T2D (ClinicalTrials.gov: NCT06066515). MATERIALS AND METHODS: Participants aged ≥18 years with BMI ≥30 or ≥27 kg/m2 with ≥1 obesity complication without T2D were randomized 1:1:1 to double-blind, once-weekly, subcutaneous injections of survodutide (up-titrated to 3.6 or 6.0 mg) or placebo for 76 weeks. The primary endpoints are percent body weight change and achievement of body weight reduction ≥5% from baseline to Week 76. Efficacy and safety analyses will include all randomized and treated participants. RESULTS: At baseline, participants (n = 725 from 14 countries) had a mean age of 47.1 years, BMI 37.9 kg/m2, and waist circumference 115.2 cm. Most participants (59.4%) were female; 47.3% were from North America, 21.0% from Europe, and 20.0% from East Asia. Obesity complications included hypertension (40.0%), dyslipidaemia (33.7%), and prediabetes (30.2%). Mean haemoglobin A1c was 5.5%, estimated glomerular filtration rate 93.0 mL/min/1.73 m2, systolic/diastolic blood pressure 127.0/82.7 mmHg, and low-density lipoprotein cholesterol 116.4 mg/dL; 21.8% were taking lipid-lowering drugs. CONCLUSIONS: SYNCHRONIZE-1 will determine the efficacy, safety, and tolerability of survodutide, a glucagon receptor/GLP-1 receptor dual agonist, for weight loss in a representative cohort of people with obesity without T2D.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

FIGURE 1FIGURE 1 SYNCHRONIZE‐1 trial design. This is a multinational, randomized, double‐blind, placebo‐controlled, phase 3 clinical trial evaluating the efficacy, safety, and tolerability of survodutide as an adjunct to a reduced‐calorie diet and increased physical activity to decrease body weight in people with obesity without type 2 diabetes. *The treatment period includes an initial dose‐escalation period that may be extended if 1 or 2 re‐escalation attempts are needed due to the occurrence of gastrointestinal symptoms. EOS, end of study; EOT, end of treatment. Adapted from fig. 1 in Wharton et al., used under CC BY‐NC 4.0.
非 KM Figure
FIGURE 2FIGURE 2 Obesity complications in the overall trial cohort. AFib, atrial fibrillation; ASCVD, arteriosclerotic cardiovascular disease (defined as coronary artery disease, myocardial infarction, stroke, or peripheral artery disease); CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; DLD, dyslipidaemia; HTN, hypertension; MASH, metabolic dysfunction‐associated steatohepatitis; OSA, obstructive sleep apnoea; PreT2D, prediabetes (based on haemoglobin A1c level of ≥5.7% to < 6.5% [≥39 to < 48 mmol/mol] at baseline).
非 KM Figure